Alcohol Clinical Trials in Baltimore, Maryland
20 recruitingBaltimore, Maryland
Showing 1–20 of 20 trials
Recruiting
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
AlcoholismSubstance-Related Disorders
National Institute on Drug Abuse (NIDA)10,000 enrolled1 locationNCT06676059
Recruiting
Phase 1
Environment and Alcohol: A Pilot Study
Alcohol Use Disorder
National Institute on Drug Abuse (NIDA)44 enrolled1 locationNCT06860607
Recruiting
Phase 2
Semaglutide Therapy for Alcohol Reduction (STAR)
Alcohol Use DisorderAddiction
National Institute on Drug Abuse (NIDA)80 enrolled1 locationNCT06015893
Recruiting
Phase 1
Spironolactone in Alcohol Use Disorder (SAUD)
Alcohol Use Disorder
National Institute on Drug Abuse (NIDA)20 enrolled1 locationNCT05807139
Recruiting
Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP
Substance Use DisorderAlcohol Use Disorder
National Institute on Drug Abuse (NIDA)10,000 enrolled1 locationNCT06552741
Recruiting
Phase 3
A Study of Brenipatide in Participants With Alcohol Use Disorder
Alcohol Use Disorder
Eli Lilly and Company1,100 enrolled117 locationsNCT07219953
Recruiting
Phase 3
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
Alcohol Use Disorder
Eli Lilly and Company1,100 enrolled120 locationsNCT07219966
Recruiting
Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic Steatohepatitis
Akero Therapeutics, Inc2,150 enrolled323 locationsNCT06528314
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.762 enrolled317 locationsNCT06419374
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled361 locationsNCT06318169
Recruiting
Phase 2
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Non-Alcoholic Fatty Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis
GlaxoSmithKline42 enrolled30 locationsNCT06920043
Recruiting
Not Applicable
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
Alcoholic HepatitisAlcohol Use Disorder
Johns Hopkins University200 enrolled1 locationNCT03845205
Recruiting
Not Applicable
External Facilitation to Increase Prescribing of AUD Medications in the Psychiatric Setting
Psychiatric DisorderAlcohol-Related Disorders
University of Maryland, Baltimore40 enrolled1 locationNCT07053098
Recruiting
Not Applicable
Cerebellar Involvement in Alcohol Use Disorder (AUD)
Alcohol Use Disorder
Johns Hopkins University122 enrolled1 locationNCT05732207
Recruiting
Phase 1Phase 2
A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects
Alcohol Use Disorder
Clearmind Medicine Inc.84 enrolled4 locationsNCT05913752
Recruiting
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic SteatohepatitisNonalcoholic Fatty Liver
Target PharmaSolutions, Inc.15,000 enrolled74 locationsNCT02815891
Recruiting
Not Applicable
Alcohol Research in HIV: Relapse Prevention
Alcohol Use DisorderHIV
Johns Hopkins University150 enrolled1 locationNCT05163301
Recruiting
Not Applicable
Brief Motivational Interviewing +/- Mindfulness Training for Adolescent Alcohol Use in Pediatric Primary Care
Adolescent alcohol use
Johns Hopkins University1,500 enrolled13 locationsNCT07059078
Recruiting
Phase 1
Vaporized Cannabis Administration and Co-Administration of Alcohol on Impairment
Cannabis IntoxicationAlcohol Intoxication
Johns Hopkins University90 enrolled1 locationNCT06293040
Recruiting
Phase 2
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
Alcohol Associated Hepatitis
Intercept Pharmaceuticals80 enrolled31 locationsNCT05639543